Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis

[1] Armstrong AW(2021)Psoriasis prevalence in adults in the United States JAMA Dermatol 157 940-946

[2] Mehta MD(2019)Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics J Am Acad Dermatol 80 1029-1072

[3] Schupp CW(2015)Economic burden of psoriasis in the United States: a systematic review JAMA Dermatol 151 651-658

[4] Menter A(2020)A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis Br J Dermatol 183 548-558

[5] Strober BE(2016)Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials JAMA Dermatol 152 661-669

[6] Kaplan DH(2012)The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis J Am Acad Dermatol 66 e67-76

[7] Brezinski EA(2016)A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment J Dermatolog Treat 27 552-555

[8] Dhillon JS(2022)Work productivity in real-life employed patients with plaque psoriasis: results from the ProLOGUE study J Dermatol 49 970-978

[9] Armstrong AW(2017)Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Lancet 390 276-288

[10] Villacorta R(2023)Quality of life and patient-reported symptoms in a phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: week 28 interim analysis J Dermatolog Treat 11 1-9

[1] Armstrong AW(2021)Psoriasis prevalence in adults in the United States JAMA Dermatol 157 940-946

[2] Mehta MD(2019)Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics J Am Acad Dermatol 80 1029-1072

[3] Schupp CW(2015)Economic burden of psoriasis in the United States: a systematic review JAMA Dermatol 151 651-658

[4] Menter A(2020)A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis Br J Dermatol 183 548-558

[5] Strober BE(2016)Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials JAMA Dermatol 152 661-669

[6] Kaplan DH(2012)The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis J Am Acad Dermatol 66 e67-76

[7] Brezinski EA(2016)A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment J Dermatolog Treat 27 552-555

[8] Dhillon JS(2022)Work productivity in real-life employed patients with plaque psoriasis: results from the ProLOGUE study J Dermatol 49 970-978

[9] Armstrong AW(2017)Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Lancet 390 276-288

[10] Villacorta R(2023)Quality of life and patient-reported symptoms in a phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: week 28 interim analysis J Dermatolog Treat 11 1-9